Home
drive our discovery
now enrolling
Finch is a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.
Human-First Discovery platform
With our platform we aim to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.
Learn moreLead program
Our lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection, a debilitating and sometimes life-threatening disease.
Learn moreRecent news
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
Join us
Join us in our mission to transform the lives of patients and families fighting serious medical conditions.
Learn more